Form 10-Q AGIOS PHARMACEUTICALS, For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St futures steady with focus on Mideast talks, US-China summit
- Oil holds near two-week lows while diesel cracks hit record peak
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
Agios Pharma (AGIO) PT Raised to $44 at RBC Capital
May 3, 2024 6:34 AM EDTRBC Capital analyst Kennen MacKay raised the price target on Agios Pharma (NASDAQ: AGIO) to $44.00 (from $42.00) while maintaining a Outperform rating.
The analyst comments "Key update from the 1Q24 is the refining of ENERGIZE-T/TD readout timeline to 2Q24 (from mid-2024), which... More
